Cantargia: Pre-Clinical Data Support the Nadunolimab and RAS Inhibitor Combination - Redeye

Redeye comments on this morning's press release, in which Cantargia reports preclinical data on nadunolimab combined with RAS inhibition in pancreatic cancer (PDAC). The data were presented at the AACR pancreatic cancer conference in San Diego on 27 September.

Länk till analysen i sin helhet: https://www.redeye.se/research/1186461/cantargia-pre-clinical-data-support-the-nadunolimab-and-ras-inhibitor-combination?utm_source=finwire&utm_medium=RSS